Services

Listings
  • Felypressin Impurity E

    Felypressin Impurity E

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    An impurity of Felypressin. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found...

  • Felypressin Impurity D

    Felypressin Impurity D

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    An impurity of Felypressin. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found...

  • Felypressin Impurity C

    Felypressin Impurity C

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    An impurity of Felypressin. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found...

  • Felypressin Impurity B

    Felypressin Impurity B

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    An impurity of Felypressin. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found...

  • Felypressin Impurity A

    Felypressin Impurity A

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    An impurity of Felypressin.Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found ...

  • Delmitide

    Delmitide

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    Delmitide is a TNF-alpha production inhibitor potentially for the treatment of chemotherapy-induced diarrhea. https://www.creative-peptides.com/product/delmitide-item-10-101-147-34916.html

  • ACT1

    ACT1

    Drug Development Shirley (New York) August 5, 2020 Check with publisher

    ACT1, a synthetic peptide designed to mimic the C-terminus of the gap junction protein connexin 43 (Cx43), with high binding specificity to the tight junction associated protein zona occludens (ZO-1). https://www.creative-peptides.com/product/act1-it...

  • KAI-1455

    KAI-1455

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and ...

  • KAI-1678

    KAI-1678

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    KAI-1678 is an inhibitor of epsilon protein kinase C in the treatment of neuropathic pain in patients with PHN. https://www.creative-peptides.com/product/kai-item-10-101-144-34913.html

  • Delcasertib

    Delcasertib

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    Delcasertib,a Novel δ-Protein Kinase C Inhibitor,is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide conjugated reversibly to the cell-penetrating peptide via a disulfide bond. https://www.creative-peptides.com/product/delcasertib-...

  • TAT-NR2B9c

    TAT-NR2B9c

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    Tat-NR2B9c (NA-1) is an peptide that inhibits PSD-95, thus disrupting binding to N-methyl-D-aspartate receptors (NMDARs) and neuronal nitric oxide synthases (nNOS) and reducing excitoxicity induced by cerebral ischemia. https://www.creative-peptides....

  • XG 102

    XG 102

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    XG-102, a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase, was shown efficient in the treatment of experimental uveitis. Research show that XG-102 peptide has potential for treating intraocular inflammation. https://www.creative...